Suppr超能文献

耗竭的 CD8 T 细胞亚群差异介导肿瘤控制并对检查点阻断产生反应。

Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade.

机构信息

Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

出版信息

Nat Immunol. 2019 Mar;20(3):326-336. doi: 10.1038/s41590-019-0312-6. Epub 2019 Feb 18.

Abstract

T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such therapy acts on a specific subpopulation of exhausted CD8 tumor-infiltrating lymphocytes (TILs). Dysfunctional CD8 TILs possess canonical epigenetic and transcriptional features of exhaustion that mirror those seen in chronic viral infection. Exhausted CD8 TILs include a subpopulation of 'progenitor exhausted' cells that retain polyfunctionality, persist long term and differentiate into 'terminally exhausted' TILs. Consequently, progenitor exhausted CD8 TILs are better able to control tumor growth than are terminally exhausted T cells. Progenitor exhausted TILs can respond to anti-PD-1 therapy, but terminally exhausted TILs cannot. Patients with melanoma who have a higher percentage of progenitor exhausted cells experience a longer duration of response to checkpoint-blockade therapy. Thus, approaches to expand the population of progenitor exhausted CD8 T cells might be an important component of improving the response to checkpoint blockade.

摘要

T 细胞功能障碍是许多癌症的标志,但 T 细胞功能障碍的基础以及抗体阻断抑制性受体 PD-1(抗 PD-1)如何重新激活 T 细胞的机制尚不完全清楚。在这里,我们表明,这种治疗作用于耗尽的 CD8 肿瘤浸润淋巴细胞(TIL)的一个特定亚群。功能失调的 CD8 TIL 具有衰竭的典型表观遗传和转录特征,与慢性病毒感染中观察到的特征相似。耗尽的 CD8 TIL 包括一个“祖细胞衰竭”细胞的亚群,它们保持多功能性,长期存在并分化为“终末衰竭”的 TIL。因此,祖细胞衰竭的 CD8 TIL 比终末衰竭的 T 细胞更能控制肿瘤生长。祖细胞衰竭的 TIL 可以对抗 PD-1 治疗作出反应,但终末衰竭的 TIL 则不能。患有黑色素瘤的患者,其祖细胞衰竭细胞的比例较高,对检查点阻断治疗的反应持续时间较长。因此,扩大祖细胞衰竭 CD8 T 细胞群体的方法可能是提高检查点阻断反应的一个重要组成部分。

相似文献

1
Subsets of exhausted CD8 T cells differentially mediate tumor control and respond to checkpoint blockade.
Nat Immunol. 2019 Mar;20(3):326-336. doi: 10.1038/s41590-019-0312-6. Epub 2019 Feb 18.
4
5
Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1CD8 Tumor-Infiltrating T Cells.
Immunity. 2019 Jan 15;50(1):181-194.e6. doi: 10.1016/j.immuni.2018.11.014. Epub 2019 Jan 8.
6
PD-1 blockade-unresponsive human tumor-infiltrating CD8 T cells are marked by loss of CD28 expression and rescued by IL-15.
Cell Mol Immunol. 2021 Feb;18(2):385-397. doi: 10.1038/s41423-020-0427-6. Epub 2020 Apr 24.
8
Immune-Checkpoint Blockade Opposes CD8 T-cell Suppression in Human and Murine Cancer.
Cancer Immunol Res. 2019 Mar;7(3):510-525. doi: 10.1158/2326-6066.CIR-18-0054. Epub 2019 Feb 6.
9
Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8 T Cells is Determined by Their Differentiation Status in Glioblastoma.
Clin Cancer Res. 2019 Apr 15;25(8):2549-2559. doi: 10.1158/1078-0432.CCR-18-2564. Epub 2019 Jan 18.

引用本文的文献

2
Enhancing natural killer cell anti-tumour activity through macrophage manipulation.
Front Immunol. 2025 Aug 29;16:1656925. doi: 10.3389/fimmu.2025.1656925. eCollection 2025.
4
Within and beyond the tumor: Mechanisms of glioblastoma-induced immunosuppression.
Neurooncol Adv. 2025 Sep 9;7(Suppl 4):iv4-iv18. doi: 10.1093/noajnl/vdaf006. eCollection 2025 Sep.
6
Immunotherapy Resistance and Therapeutic Strategies in PD-L1 High Expression Non-Small Cell Lung Cancer.
Onco Targets Ther. 2025 Aug 29;18:953-966. doi: 10.2147/OTT.S539978. eCollection 2025.
9
Commentary: Immunogenomic characteristics and prognostic implications of terminally exhausted CD8+ T cells in colorectal cancers.
Front Immunol. 2025 Aug 13;16:1654000. doi: 10.3389/fimmu.2025.1654000. eCollection 2025.
10
Spatial TCR clonality and clonal expansion in the in situ microenvironment of non-small cell lung cancer.
J Immunother Cancer. 2025 Aug 27;13(8):e012089. doi: 10.1136/jitc-2025-012089.

本文引用的文献

1
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.
Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038.
2
High-dimensional single cell analysis identifies stem-like cytotoxic CD8 T cells infiltrating human tumors.
J Exp Med. 2018 Oct 1;215(10):2520-2535. doi: 10.1084/jem.20180684. Epub 2018 Aug 28.
4
T Cell Dysfunction in Cancer.
Cancer Cell. 2018 Apr 9;33(4):547-562. doi: 10.1016/j.ccell.2018.03.012.
5
Comparative transcriptome analysis reveals distinct genetic modules associated with Helios expression in intratumoral regulatory T cells.
Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2162-2167. doi: 10.1073/pnas.1720447115. Epub 2018 Feb 9.
6
Intratumoral CD8 T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity.
Cancer Immunol Res. 2018 Jan;6(1):14-24. doi: 10.1158/2326-6066.CIR-17-0249. Epub 2017 Nov 2.
7
Resistance to checkpoint blockade therapy through inactivation of antigen presentation.
Nat Commun. 2017 Oct 26;8(1):1136. doi: 10.1038/s41467-017-01062-w.
8
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma.
Blood. 2017 Nov 30;130(22):2420-2430. doi: 10.1182/blood-2017-03-770719. Epub 2017 Sep 11.
9
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Cell. 2017 Sep 7;170(6):1120-1133.e17. doi: 10.1016/j.cell.2017.07.024. Epub 2017 Aug 10.
10
Chromatin states define tumour-specific T cell dysfunction and reprogramming.
Nature. 2017 May 25;545(7655):452-456. doi: 10.1038/nature22367. Epub 2017 May 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验